Anixa Biosciences, Inc. (ANIX) vs Neumora Therapeutics, Inc. Common Stock (NMRA)
A side-by-side comparison of Anixa Biosciences, Inc. and Neumora Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANIX
Anixa Biosciences, Inc.
$3.09HealthcareDelayed quote: Oct 6, 2026, 2:30 PM EDT
NMRA
Neumora Therapeutics, Inc. Common Stock
$0.48HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
Total return — ANIX vs NMRA
growth of $100 · dividends reinvested · last 3yANIX -12.5% (-4.3%/yr)NMRA -96.8% (-68.1%/yr)ANIX compounded faster over this window
Log scale — wide-divergence pair
ANIX NMRA
ANIX vs NMRA: by the numbers
- •ANIX is the larger company ($105M vs $89M market cap).
Metrics side by side
Valuation
| Metric | ANIX | NMRA |
|---|---|---|
| P/B ratio | 7.26 | 2.00 |
Profitability
| Metric | ANIX | NMRA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -72.02% | -477.87% |
| ROIC | -82.35% | -216.05% |
Growth (annualized)
| Metric | ANIX | NMRA |
|---|---|---|
| Total return CAGR (5Y) | -8.26% | N/A |
Go deeper
Dig into the metrics
Anixa Biosciences ROENeumora Therapeutics, Inc. Common Stock ROEAnixa Biosciences operating marginNeumora Therapeutics, Inc. Common Stock operating marginAnixa Biosciences revenue growthNeumora Therapeutics, Inc. Common Stock revenue growthAnixa Biosciences free cash flowNeumora Therapeutics, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.